Responses
Clinical/translational cancer immunotherapy
Original research
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
Compose a Response to This Article
Other responses
No responses have been published for this article.